{"id":"olmesartan-medoxomil-tablets","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Dizziness"},{"rate":"1-3","effect":"Hyperkalemia"},{"rate":"2-4","effect":"Headache"},{"rate":"1-2","effect":"Fatigue"},{"rate":"1-3","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, an angiotensin II receptor blocker (ARB). It selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues, blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This leads to vasodilation, reduced peripheral vascular resistance, and decreased blood pressure.","oneSentence":"Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:08.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Reduction of cardiovascular risk in patients with hypertension"}]},"trialDetails":[{"nctId":"NCT02483936","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Arterial Hypertension","enrollment":""},{"nctId":"NCT02493322","phase":"PHASE3","title":"Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT05411887","phase":"","title":"Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hyperlipidemias, Hypertension","enrollment":2845},{"nctId":"NCT05660135","phase":"","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hypertension, Dyslipidemias","enrollment":4000},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT04120753","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-08-26","conditions":"Hypertension, Dyslipidemias","enrollment":106},{"nctId":"NCT01019590","phase":"PHASE1","title":"Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT00649623","phase":"PHASE1","title":"Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-12","conditions":"Healthy","enrollment":36},{"nctId":"NCT00648219","phase":"PHASE1","title":"Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-12","conditions":"Healthy","enrollment":36},{"nctId":"NCT01020214","phase":"PHASE1","title":"Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT00751829","phase":"PHASE3","title":"Isolated Systolic Hypertension in the Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-07","conditions":"Isolated Systolic Hypertension","enrollment":417},{"nctId":"NCT05033535","phase":"PHASE2","title":"s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2020-07-01","conditions":"Essential Hypertension","enrollment":10},{"nctId":"NCT00441350","phase":"PHASE3","title":"Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension","status":"COMPLETED","sponsor":"Menarini Group","startDate":"2007-07","conditions":"Hypertension","enrollment":1004},{"nctId":"NCT03015311","phase":"NA","title":"Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2017-01-15","conditions":"Primary Hypertension","enrollment":8000},{"nctId":"NCT01870739","phase":"PHASE2","title":"A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Hypertension","enrollment":115},{"nctId":"NCT00523744","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Hypertension","enrollment":257},{"nctId":"NCT04138888","phase":"PHASE1","title":"A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2019-10-31","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT03951051","phase":"PHASE1","title":"The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2019-05-06","conditions":"Bioequivalence","enrollment":32},{"nctId":"NCT00902538","phase":"PHASE3","title":"Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Essential Hypertension","enrollment":2204},{"nctId":"NCT00430950","phase":"PHASE3","title":"Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-02","conditions":"Essential Hypertension","enrollment":1011},{"nctId":"NCT00923091","phase":"PHASE3","title":"Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-06","conditions":"Essential Hypertension","enrollment":2689},{"nctId":"NCT00430508","phase":"PHASE3","title":"Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-02","conditions":"Essential Hypertension","enrollment":972},{"nctId":"NCT00791258","phase":"PHASE4","title":"A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Hypertension","enrollment":999},{"nctId":"NCT01838850","phase":"PHASE3","title":"Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","status":"COMPLETED","sponsor":"Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":344},{"nctId":"NCT01132768","phase":"PHASE4","title":"The Confirmatory Olmesartan Plaque Regression Study","status":"TERMINATED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-05","conditions":"Essential Hypertension, Carotid Plaque","enrollment":114},{"nctId":"NCT00679484","phase":"PHASE3","title":"Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24","status":"TERMINATED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-06","conditions":"Chronic Heart Failure, High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level","enrollment":400},{"nctId":"NCT00891267","phase":"PHASE3","title":"Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-10","conditions":"Metabolic Syndrome, Hypertension","enrollment":60},{"nctId":"NCT00676845","phase":"PHASE3","title":"Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2008-08","conditions":"Metabolic Syndrome, Hypertension","enrollment":133},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT03753477","phase":"PHASE1","title":"Clinical Trial to Investigate the Efficacy and Safety of DWJ1351","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-12-22","conditions":"Healthy","enrollment":64},{"nctId":"NCT00430638","phase":"PHASE4","title":"A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-12","conditions":"Hypertension","enrollment":278},{"nctId":"NCT02609490","phase":"PHASE3","title":"Azilsartan in Chinese Patients With Mild and Moderate Hypertension","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-09","conditions":"Hypertension","enrollment":304},{"nctId":"NCT03319706","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2010-08","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT03318354","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2010-05","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT00858702","phase":"PHASE4","title":"Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2005-02","conditions":"Hypertension","enrollment":105},{"nctId":"NCT01611077","phase":"PHASE4","title":"Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2012-01","conditions":"Hypertension","enrollment":88},{"nctId":"NCT01785472","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":1438},{"nctId":"NCT02962258","phase":"PHASE1","title":"BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT02962336","phase":"PHASE1","title":"Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT00403481","phase":"PHASE4","title":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-11","conditions":"Hypertension","enrollment":192},{"nctId":"NCT01377285","phase":"PHASE4","title":"Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-06","conditions":"Chronic Renal Failure","enrollment":350},{"nctId":"NCT00151775","phase":"PHASE2, PHASE3","title":"Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-05","conditions":"Hypertension","enrollment":362},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT01613209","phase":"PHASE3","title":"Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2011-12","conditions":"Hypertension","enrollment":83},{"nctId":"NCT01876368","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Hypertension","enrollment":376},{"nctId":"NCT01615198","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":588},{"nctId":"NCT01599104","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Essential Hypertension","enrollment":1161},{"nctId":"NCT02407210","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-01","conditions":"Essential Hypertension","enrollment":304},{"nctId":"NCT02360956","phase":"PHASE4","title":"Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2014-12","conditions":"Coronary Atherosclerosis","enrollment":100},{"nctId":"NCT02058472","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2013-12","conditions":"Healthy Adult Volunteers","enrollment":30},{"nctId":"NCT01219556","phase":"","title":"Xirtam H Combination In the Treatment of Hypertension Evaluation Study.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-11","conditions":"Hypertension","enrollment":8704},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Safety","enrollment":153},{"nctId":"NCT01992796","phase":"PHASE3","title":"Angiotensin II Antagonist in Severe Sepsis","status":"UNKNOWN","sponsor":"University of Salerno","startDate":"2014-01","conditions":"Severe Sepsis","enrollment":300},{"nctId":"NCT01907373","phase":"PHASE4","title":"Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Central South University","startDate":"2009-08","conditions":"Drug Interaction of Olmesartan in Healthy Chinese Volunteers","enrollment":12},{"nctId":"NCT01831479","phase":"PHASE1","title":"Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Severance Hospital","startDate":"2011-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01823900","phase":"PHASE1","title":"Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Severance Hospital","startDate":"2012-01","conditions":"Healthy","enrollment":58},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT00098137","phase":"PHASE3","title":"Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation","status":"COMPLETED","sponsor":"Atrial Fibrillation Network","startDate":"2005-01","conditions":"Heart Disease, Arrhythmia, Atrial Fibrillation","enrollment":422},{"nctId":"NCT01493856","phase":"PHASE1","title":"A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2012-01","conditions":"Healthy Volunteers","enrollment":58},{"nctId":"NCT01415466","phase":"PHASE1","title":"Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2011-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00696241","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":1275},{"nctId":"NCT01180205","phase":"PHASE4","title":"Telmisartan, Amlodipine and Flow Mediated Dilation","status":"UNKNOWN","sponsor":"Johannes Gutenberg University Mainz","startDate":"2010-08","conditions":"Hypertension","enrollment":576},{"nctId":"NCT00141453","phase":"PHASE3","title":"ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2003-04","conditions":"Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria","enrollment":577},{"nctId":"NCT00696436","phase":"PHASE3","title":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Hypertension","enrollment":1291},{"nctId":"NCT00362115","phase":"PHASE2","title":"Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Hypertension","enrollment":449},{"nctId":"NCT00949884","phase":"PHASE4","title":"Olmesartan Comparison to Losartan in Hypertensive Subjects","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-08","conditions":"Hypertension","enrollment":941},{"nctId":"NCT00311155","phase":"PHASE4","title":"Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2006-03","conditions":"Essential Hypertension","enrollment":694},{"nctId":"NCT00151827","phase":"PHASE3","title":"Olmesartan Medoxomil in Hypertension and Renal Impairment","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2003-08","conditions":"Essential Hypertension, Renal Impairment","enrollment":393},{"nctId":"NCT00856271","phase":"PHASE3","title":"Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2004-08","conditions":"Essential Hypertension","enrollment":287},{"nctId":"NCT00872586","phase":"PHASE3","title":"Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-08","conditions":"Essential Hypertension","enrollment":304},{"nctId":"NCT00914524","phase":"PHASE2","title":"Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2005-01","conditions":"Chronic Glomerulonephritis, Diabetic Nephropathy","enrollment":49},{"nctId":"NCT00654745","phase":"PHASE4","title":"18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-05","conditions":"Type 2 Diabetes, Hypertension","enrollment":207},{"nctId":"NCT00759551","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-08","conditions":"Hypertension","enrollment":555},{"nctId":"NCT00151814","phase":"PHASE1","title":"Olmesartan Pediatric Pharmacokinetic (PK) Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-09","conditions":"Hypertension","enrollment":24},{"nctId":"NCT00185159","phase":"PHASE3","title":"Olmesartan Medoxomil in Diabetes Mellitus","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2004-10","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Disease, Kidney Disease","enrollment":4449},{"nctId":"NCT00527514","phase":"PHASE3","title":"Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-09","conditions":"Hypertension","enrollment":185},{"nctId":"NCT00412932","phase":"PHASE4","title":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-12","conditions":"Hypertension","enrollment":178},{"nctId":"NCT00857285","phase":"PHASE3","title":"Olmesartan Medoxomil Versus Losartan in Patients With Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-05","conditions":"Essential Hypertension","enrollment":130},{"nctId":"NCT00890591","phase":"PHASE4","title":"Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-08","conditions":"Essential Hypertension","enrollment":144},{"nctId":"NCT00772499","phase":"PHASE4","title":"Vascular Improvement With Olmesartan Medoxomil Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypertension","enrollment":100},{"nctId":"NCT00751751","phase":"PHASE3","title":"Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-06","conditions":"Essential Hypertension","enrollment":441},{"nctId":"NCT00185172","phase":"PHASE3","title":"Olmesartan in Essential Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2002-01","conditions":"Essential Hypertension","enrollment":2333},{"nctId":"NCT00185185","phase":"PHASE3","title":"Olmesartan Medoxomil in Atherosclerosis","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2001-11","conditions":"Essential Hypertension, Atherosclerotic Cardiovascular Disease","enrollment":165}],"_emaApprovals":[],"_faersSignals":[{"count":15,"reaction":"DIARRHOEA"},{"count":12,"reaction":"DRUG INEFFECTIVE"},{"count":12,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":11,"reaction":"WEIGHT DECREASED"},{"count":10,"reaction":"PRODUCT QUALITY ISSUE"},{"count":8,"reaction":"DEHYDRATION"},{"count":7,"reaction":"HEADACHE"},{"count":7,"reaction":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS"},{"count":6,"reaction":"BLOOD PRESSURE INCREASED"},{"count":6,"reaction":"DIZZINESS"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Benicar"],"phase":"marketed","status":"active","brandName":"Olmesartan medoxomil tablets","genericName":"Olmesartan medoxomil tablets","companyName":"Lee's Pharmaceutical Limited","companyId":"lee-s-pharmaceutical-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Reduction of cardiovascular risk in patients with hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}